ストックスクリーナーアプリを入手
1.96
12.00%
0.21
アフターアワーズ：
1.82
-0.14
-7.14%
前日終値:
$1.75
開ける：
$1.71
24時間の取引高:
1.27M
Relative Volume:
1.21
時価総額：
$115.93M
収益：
-
当期純損益:
$-30.04M
株価収益率:
-1.2405
EPS:
-1.58
ネットキャッシュフロー:
$-27.38M
1週間 パフォーマンス:
+51.94%
1か月 パフォーマンス:
+45.19%
6か月 パフォーマンス:
+17.37%
1年 パフォーマンス:
-27.94%
1日の値動き範囲:
$1.67
$2.01
1週間の範囲:
$1.3405
$2.05
52週間の値動き範囲:
$0.8301
$2.90
Regulus Therapeutics Inc Stock (RGLS) Company Profile
名前
Regulus Therapeutics Inc
セクター
電話
858-202-6300
住所
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.96 | 115.93M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | 開始されました | Oppenheimer | Outperform |
| 2024-03-18 | 開始されました | Leerink Partners | Outperform |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 開始されました | Leerink Partners | Outperform |
| 2017-06-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-06 | 繰り返されました | Wedbush | Outperform |
| 2017-01-30 | ダウングレード | Needham | Buy → Hold |
| 2017-01-30 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-11-02 | 繰り返されました | Needham | Buy |
| 2016-07-25 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | FBR Capital | Outperform |
| 2016-06-28 | 繰り返されました | Needham | Buy |
| 2016-06-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-04-13 | 開始されました | Chardan Capital Markets | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-06-09 | 開始されました | Guggenheim | Buy |
| 2015-04-21 | 再開されました | FBR Capital | Outperform |
| 2014-11-24 | 開始されました | Deutsche Bank | Buy |
| 2014-08-07 | 繰り返されました | FBR Capital | Outperform |
| 2013-08-14 | 繰り返されました | Needham | Buy |
すべてを表示
Regulus Therapeutics Inc (RGLS) 最新ニュース
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - Marketscreener.com
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo Finance
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
Regulus: Q4 Earnings Snapshot - Bakersfield.com
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR.com
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR.com
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Management Takes Center Stage at Major Healthcare ConferenceKey Details Inside - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
Regulus Therapeutics Inc (RGLS) 財務データ
収益
当期純利益
現金流量
EPS
2.00%
大文字化:
|
ボリューム (24 時間):